Protein O-GlcNAcylation and hexokinase mitochondrial dissociation drive heart failure with preserved ejection fraction
- PMID: 40267914
- PMCID: PMC12221816
- DOI: 10.1016/j.cmet.2025.04.001
Protein O-GlcNAcylation and hexokinase mitochondrial dissociation drive heart failure with preserved ejection fraction
Abstract
Heart failure with preserved ejection fraction (HFpEF) is a common cause of morbidity and mortality worldwide, but its pathophysiology remains unclear. Here, we report a mouse model of HFpEF and show that hexokinase (HK)-1 mitochondrial binding in endothelial cells (ECs) is critical for protein O-GlcNAcylation and the development of HFpEF. We demonstrate increased mitochondrial dislocation of HK1 within ECs in HFpEF mice. Mice with deletion of the mitochondrial-binding domain of HK1 spontaneously develop HFpEF and display impaired angiogenesis. Spatial proximity of dislocated HK1 and O-linked N-acetylglucosamine transferase (OGT) causes increased OGT activity, shifting the balance of the hexosamine biosynthetic pathway intermediates into the O-GlcNAcylation machinery. EC-specific overexpression of O-GlcNAcase and an OGT inhibitor reverse angiogenic defects and the HFpEF phenotype, highlighting the importance of protein O-GlcNAcylation in the development of HFpEF. Our study demonstrates a new mechanism for HFpEF through HK1 cellular localization and resultant protein O-GlcNAcylation, and provides a potential therapy for HFpEF.
Keywords: HFpEF; O-GlcNAcylation; endothelial cell; hexokinase 1; mitochondria.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests H.A. and Y.T. are listed as inventors on a patent application (18/412,362) filed on January 12, 2024, related to the subject matter of this research.
Update of
-
[WITHDRAWN] Hexokinase-1 mitochondrial dissociation and protein O-GlcNAcylation drive heart failure with preserved ejection fraction.Res Sq [Preprint]. 2023 Jan 25:rs.3.rs-2448086. doi: 10.21203/rs.3.rs-2448086/v1. Res Sq. 2023. Update in: Cell Metab. 2025 Jul 1;37(7):1584-1600.e10. doi: 10.1016/j.cmet.2025.04.001. PMID: 36747777 Free PMC article. Updated. Preprint.
References
-
- Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Yancy CW, Young JB, et al. (2007). Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 50, 768–777. 10.1016/j.jacc.2007.04.064. - DOI - PubMed
-
- Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, and Carson PE (2011). Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 4, 324–331. 10.1161/CIRCHEARTFAILURE.110.959890. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous